|
contents | business | |||||||
| Toumaz Technology Delivers Technology Platform for DIAdvisor Toumaz Holdings announces that its wholly-owned subsidiary Toumaz Technology has successfully completed the timely delivery of the hardware, software and sensors that are being used to capture large-scale data in the first phase of DIAdvisor's clinical trial. DIAdvisor is a large-scale integrating project (IP) aiming at the development of a prediction-based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes. DIAdvisor will allow patients to actively and accurately predict their short-term blood glucose outlook at any time by analysing data retrieved from glucose measurements, insulin delivery data and specific patient parameters. The key data, captured by non-intrusive body-worn wireless monitors including those based on Toumaz Technology's Sensium platform, will be used to create physiological mathematical modelling, control and prediction algorithms. The resulting analysis and prediction information will be wirelessly transmitted to a healthcare provider advisory service, with recommended action and treatment advice presented to the patient via a handheld mobile device such as a Personal Digital Assistant (PDA). The first year of the project oversaw the implementation of a large-scale data-acquisition clinical trial involving 90 patients across three sites in Europe; France, Italy and Czech Republic. As leaders of Workpackage 4, Toumaz Technology is responsible for the device platform development, including hardware, software and sensors and has ensured the successful and timely delivery of this device platform in the first year of the project. The collaborative DIAdvisor project received a €7.1 million European Community Grant in April 2008 and the large-scale four year research and development project is being coordinated by Novo Nordisk A/S, a world leader in diabetes care. It will be delivered by a consortium of 13 medical, industrial and academic partners, including the European Division of the International Diabetes Federation. The DIAdvisor project consortium recently held its second General Assembly (GA2), to review progress at end of the first year of the project. The GA2 meeting was hosted by consortium members Toumaz Technology at the Institute of Biomedical Engineering at Imperial College London. write your comments about the article :: © 2009 Computing News :: home page |